NEW DELHI: The Subject Expert Committee of the Central Drug Standard Control Organisation on Friday has held that the data provided by Bharat Biotech for its coronavirus vaccine Covaxin is not sufficient for grant of emergency use approval and has asked for more information, top sources said.
Earlier on Friday, the expert committee, which is tasked with vetting covid-19 vaccine proposals, recommended emergency licensure for the Serum Institute of India-manufactured Covishield . It become the first vaccine to secure recommendation for emergency use in India.
The Pune-based Serum Institute has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing Covishield while Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) for Covaxin .
Big Win In India s Fight Against Covid-19: Covishield Vaccine Gets Conditional Approval
SII s Covishield vaccine (Pic Via Twitter)
The 10-member Subject Expert Committee (SEC) of India s Central Drug Standard Control Organisation (CDSCO) today (1 January) approved emergency use authorisation of the Oxford-AstraZeneca coronavirus vaccine Covishield .
As per reports the SEC recommended in favour of the emergency use authorisation to the DCGI subject to certain conditions. The vaccine has been developed by scientists at the UK s Oxford University and is produced by AstraZeneca.
The expert panel had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute of India, the manufacturer of Covishield, and Bharat Biotech for its Covaxin.
Key meeting on vaccine approval underway, Bharat Biotech to begin presentation shortly
By IANS |
Published on
Fri, Jan 1 2021 15:21 IST |
0 Views
Key meeting on vaccine approval underway, Bharat Biotech to begin presentation shortly. Image Source: IANS News
New Delhi, Jan 1 : Serum Institute of India has concluded its presentation before the 10-member Subject Expert Committee of the Drug Regulator for the approval of its coronavirus vaccine. Bharat Biotech will commence presentation of its data shortly, an official source said on Friday. Serum Institute of India has concluded its presentation. Bharat Biotech will start presenting its data shortly, the source told IANS.
A key meeting of the Subject Expert Committee of the Central Drug Standard Control Organization is currently underway to take a call on the emergency use authorisation sought by Serum Institute of India and Bharat Biotech for their coronavirus vaccines candidates. The panel is likely
Oxford-AstraZeneca Covishield vaccine likely to get nod in India daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.